Allison Frisbee Net Worth

The estimated Net Worth of Allison Frisbee is at least $209 Tausend dollars as of 21 February 2024. Allison Frisbee owns over 12,105 units of Kronos Bio stock worth over $196,309 and over the last few years Allison sold KRON stock worth over $12,710.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Allison Frisbee KRON stock SEC Form 4 insiders trading

Allison has made over 1 trades of the Kronos Bio stock since 2024, according to the Form 4 filled with the SEC. Most recently Allison sold 12,105 units of KRON stock worth $12,710 on 21 February 2024.

The largest trade Allison's ever made was selling 12,105 units of Kronos Bio stock on 21 February 2024 worth over $12,710. On average, Allison trades about 12,105 units every 0 days since 2024. As of 21 February 2024 Allison still owns at least 204,510 units of Kronos Bio stock.

You can see the complete history of Allison Frisbee stock trades at the bottom of the page.

What's Allison Frisbee's mailing address?

Allison's mailing address filed with the SEC is C/O KRONOS BIO, INC., 1300 SO. EL CAMINO REAL, SUITE 400, SAN MATEO, CA, 94402.

Insiders trading at Kronos Bio

Over the last 4 years, insiders at Kronos Bio have traded over $6,434,800 worth of Kronos Bio stock and bought 7,151,111 units worth $30,320,233 . The most active insiders traders include John C Martin, Norbert W Bischofberger und Arie Belldegrun. On average, Kronos Bio executives and independent directors trade stock every 33 days with the average trade being worth of $178,391. The most recent stock trade was executed by Norbert W Bischofberger on 27 June 2024, trading 615,518 units of KRON stock currently worth $732,466.

What does Kronos Bio do?

Kronos Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel cancer therapeutics. The company's product engine focuses on dysregulated transcription factors and the transcriptional regulatory networks that drive oncogenic activity. Its lead product candidate is entospletinib (ENTO), is an orally administered, selective spleen tyrosine kinase inhibitor for acute myeloid leukemia patients. The company planned registrational phase 3 clinical trial of ENTO in combination with induction chemotherapy in acute myeloid leukemia patients with NPM1 mutations. It is also developing KB-0742, an orally bioavailable inhibitor of cyclin dependent kinase 9 for the treatment of MYC-amplified solid tumors, which is in phase 1/2 clinical trial. The company was incorporated in 2017 and is headquartered in San Mateo, California.

Complete history of Allison Frisbee stock trades at Kronos Bio

Kronos Bio executives and stock owners

Kronos Bio executives and other stock owners filed with the SEC include:

• Jorge F. DiMartino M.D., Ph.D.,
  Chief Medical Officer & Exec. VP of Clinical Devel.
• Dr. Norbert W. Bischofberger Ph.D.,
  Pres, CEO & Director
• Dr. Yasir B. Al-Wakeel BCh, BM, MA,
  CFO & Head of Corp. Devel.
• Dr. Norbert W. Bischofberger,
  Pres, CEO & Director
• David M. Tanen J.D.,
  Sec. & Director
• Joshua A. Kazam,
  Co-Founder & Director
• Marni Kottle,
  Sr. VP of Corp. Communications & Investor Relations
• Dr. Christopher Dinsmore Ph.D.,
  Chief Scientific Officer
• Barbara A. Kosacz J.D.,
  COO & Gen. Counsel
• Charles Lin Ph.D.,
  Sr. VP of Biology
• Dr. Pasit Phiasivongsa Ph.D.,
  Sr. VP of Pharmaceutical Devel.
• Stephanie Yao,
  Exec. Director of Investor Relations & Corp. Communications
• Dr. Christopher Dinsmore,
  Chief Scientific Officer
• Barbara A. Kosacz,
  COO & Gen. Counsel
• Dr. Yasir B. Al-Wakeel,
  CFO & Head of Corp. Devel.
• Norbert W Bischofberger,
  PRESIDENT & CEO
• Barbara Kosacz,
  COO & General Counsel
• Yasir B. Al Wakeel,
  Chief Financial Officer
• Christopher Dinsmore,
  Chief Scientific Officer
• Norbert W. & Inger A. Revoc...,
  10% owner
• Arie Belldegrun,
  
• Rebecka Belldegrun,
  Director
• Jakob Loven,
  Director
• John C Martin,
  Director
• Otello Stampacchia,
  Director
• Fund V, L.P.Omega Fund V Gp...,
  
• Jorge Di Martino,
  Chief Medical Officer & VP
• Backer Marianne De,
  Director
• Roshawn A. Blunt,
  
• Roger D Dansey,
  
• David M Tanen,
  
• Joshua A Kazam,
  
• Allison Frisbee,
  SR VP, CORP OPERATIONS & LEGAL
• Charles Y Lin,
  SR VP, RESEARCH & DEVELOPMENT
• Elizabeth A Olek,
  SR VP, CLINICAL SCIENCE
• Taiyin Yang,
  
• Elena Ridloff,
  
• Katherine V Stultz,
  
• Deborah Knobelman,
  Chief Financial Officer